Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap(Memorial Sloan Kettering Cancer Center), Andrew J. Wagner(Dana-Farber Cancer Institute), John H. Healey(Memorial Sloan Kettering Cancer Center), Charles Peterfy, Kristen N. Ganjoo(Stanford Medicine), Javier Martín‐Broto(Hospital Universitario Fundación Jiménez Díaz), Hans Gelderblom(Leiden University Medical Center), Michiel A. J. van de Sande(Leiden University Medical Center), Dale E. Shuster(Daiichi Sankyo (United States)), Sebastian Bauer(Berliner Hochschule für Technik), Henry H. Hsu, Heather L. Gelhorn(Ithaka Harbors), Jean‐Yves Blay(Université Claude Bernard Lyon 1), Christopher W. Ryan(Oregon Health & Science University), Sandra Tong-Starksen, David M. Thomas(The Kinghorn Cancer Centre), Silvia Stacchiotti(Fondazione IRCCS Istituto Nazionale dei Tumori), Thierry Alcindor(McGill University), Jayesh Desai(Peter MacCallum Cancer Centre), Emanuela Palmerini(Istituto Ortopedico Rizzoli), Qiang Wang(Daiichi Sankyo (United States)), Paul Lin, Antoine Yver(Daiichi Sankyo (United States))
Cited by 472
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k